Bioprojet Pharma

Sleep Disorders and Wakefulness

Bioprojet Pharma focuses on narcolepsy, narcolepsy with cataplexy, and related excessive daytime sleepiness, with clinical activity spanning both paediatric and adult populations.

  • Cataplexy
  • Excessive daytime sleepiness
  • Paediatric narcolepsy

The sponsor’s work in this area also includes treatment evaluation in patients with sleep-related symptoms and associated functional impairment.

Neuropsychiatric and Behavioural Disorders

Its research portfolio includes autism spectrum disorders, obsessive-compulsive disorder, and binge eating disorder, reflecting interest in conditions affecting behaviour, cognition, and emotional regulation.

  • Autism spectrum disorder
  • Obsessive-compulsive disorder
  • Binge eating disorder

Clinical activity in these domains also extends to symptom-focused assessment in children, adolescents, and adults.

Allergic and Immune-Mediated Conditions

Bioprojet Pharma is active in anaphylaxis, atopic dermatitis, and eosinophilic esophagitis, covering acute allergic reactions as well as chronic inflammatory disease.

  • Anaphylaxis
  • Atopic dermatitis
  • Eosinophilic esophagitis

This area links allergy, dermatology, and gastrointestinal inflammation within the sponsor’s clinical research portfolio.

Movement and Neurological Disorders

The sponsor also studies essential tremor, indicating involvement in neurological conditions that affect motor control and daily functioning.

  • Essential tremor

Research in this field complements its broader interest in disorders with central nervous system involvement.

Sexual Health

Bioprojet Pharma includes primary premature ejaculation among its clinical interests, reflecting attention to male sexual health and related quality-of-life concerns.

  • Primary premature ejaculation

Clinical work in this area adds a distinct therapeutic dimension to the sponsor’s research landscape.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on the Effectiveness and Safety of BP1.7881 for Adults with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    2 1
    Investigated Diseases:
    Investigated Drugs:
    France Germany Poland
  • Study on the Effects of Pitolisant for Children and Adolescents with Autism Spectrum Disorder

    Not recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Italy Poland Spain